ArticleJACC. Advances2026
Antiplatelet Therapy and All-Cause Mortality After Transcatheter Aortic Valve Replacement: The TRITAVI Registry.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03740425 (Transfusion Requirements in Transcatheter Aortic Valve Implantation), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Transfusion Requirements in Transcatheter Aortic Valve Implantation (TRITAVI) Study
Who cites it
1 citing paper in PubMed.
- Revisiting outcomes after transcatheter aortic valve replacement: The need for a multidimensional approach to patient management.International journal of cardiology. Heart & vasculature · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrent guidelines recommend single antiplatelet therapy (SAPT) after transcatheter aortic valve replacement (TAVR) in patients without an indication for anticoagulation. This recommendation is mainly based on a better risk profile in terms of bleeding over dual antiplatelet therapy (DAPT), although data on mortality are inconclusive.
objectivesWe analyzed 6-month and 24-month mortality associated with SAPT and DAPT after femoral TAVR from the Transfusion Requirements in Transcatheter Aortic Valve Implantation registry.
methodsThe Transfusion Requirements in Transcatheter Aortic Valve Implantation is a multicenter registry including 10,071 patients undergoing TAVR. For the purpose of the present study, 4,557 patients with indication to anticoagulation, nonfemoral access, recent percutaneous coronary intervention, and procedural complications were excluded. The remaining 5,514 patients (age 81 ± 7 years, 51% males) were discharged either on SAPT (n = 3,197) or DAPT (n = 2,317).
resultsThe SAPT group, compared with the DAPT group, experienced lower 6-month all-cause mortality (2.4% vs 5.4%; log-rank P < 0.0001) and major bleeding (0.5% vs 1.3%; log-rank P = 0.001). SAPT was associated with reduced both cardiovascular (1.3%) and noncardiovascular mortality (1.1%), as compared to DAPT (2.2%, P = 0.008 and 3.2%, P = 0.0001, respectively). At 24-month follow-up, overall mortality remained significantly lower with SAPT vs DAPT (11.7% vs 14.2%; log-rank P = 0.007). Cox regression hazard model confirmed the association of DAPT with 6-month (adjusted HR: 1.69; 95% CI: 1.20-2.37; P = 0.002) and 24-month (adjusted HR: 1.21; 95% 1.01-1.46; P = 0.04) all-cause mortality.
conclusionsIn a large real-world population of all comers undergoing TAVR, SAPT was associated with a significantly lower 6-month and 24-month all-cause mortality as compared with DAPT. (Transfusion Requirements in Transcatheter Aortic Valve Implantation [TRITAVI] Study; NCT03740425).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.